Total Payments
$47,339
2024 Payments
$10,059
Companies
21
Transactions
103
Medicare Patients
1,978
Medicare Billing
$304,556
Payment Breakdown by Category
Consulting$31,417 (66.4%)
Other$10,312 (21.8%)
Food & Beverage$4,562 (9.6%)
Travel$987.62 (2.1%)
Education$60.72 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $31,417 | 25 | 66.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,912 | 3 | 12.5% |
| Food and Beverage | $4,562 | 65 | 9.6% |
| Honoraria | $4,400 | 2 | 9.3% |
| Travel and Lodging | $987.62 | 6 | 2.1% |
| Education | $60.72 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $15,266 | 29 | $0 (2024) |
| Siemens Medical Solutions USA, Inc. | $9,500 | 11 | $0 (2024) |
| Avyxa Pharma, LLC | $5,000 | 2 | $0 (2024) |
| Mylan Institutional Inc. | $4,167 | 14 | $0 (2022) |
| AMAG Pharmaceuticals, Inc. | $3,875 | 4 | $0 (2019) |
| Exelixis Inc. | $2,843 | 3 | $0 (2022) |
| Dendreon Pharmaceuticals LLC | $1,635 | 2 | $0 (2019) |
| R-Pharm US LLC | $1,320 | 2 | $0 (2019) |
| Athenex Pharmaceutical Division, LLC | $1,250 | 1 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $692.60 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,059 | 17 | Avyxa Pharma, LLC ($5,000) |
| 2023 | $16,047 | 23 | AstraZeneca Pharmaceuticals LP ($9,673) |
| 2022 | $5,337 | 15 | AstraZeneca Pharmaceuticals LP ($3,627) |
| 2021 | $294.17 | 4 | AstraZeneca Pharmaceuticals LP ($133.25) |
| 2020 | $1,559 | 4 | Athenex Pharmaceutical Division, LLC ($1,250) |
| 2019 | $12,702 | 25 | Mylan Institutional Inc. ($4,043) |
| 2018 | $869.97 | 10 | Merck Sharp & Dohme Corporation ($343.60) |
| 2017 | $471.34 | 5 | Merck Sharp & Dohme Corporation ($349.00) |
All Payment Transactions
103 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Avyxa Pharma, LLC | Docivyx (Drug), Cyclophosphamide, Posfrea | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Siemens Medical Solutions USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 11/06/2024 | Avyxa Pharma, LLC | Docivyx (Drug), Cyclophosphamide, Posfrea | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| 10/17/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $19.38 | General |
| 09/18/2024 | Siemens Medical Solutions USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 08/07/2024 | Siemens Medical Solutions USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 08/06/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $107.56 | General |
| 07/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| 06/01/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $153.97 | General |
| Category: Oncology | ||||||
| 06/01/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: Oncology | ||||||
| 05/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $26.35 | General |
| 05/14/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $16.87 | General |
| 03/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $47.01 | General |
| 03/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $32.93 | General |
| 01/24/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $16.63 | General |
| 01/10/2024 | Siemens Medical Solutions USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 12/26/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| Category: Oncology | ||||||
| 12/26/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Oncology | ||||||
| 12/07/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.95 | General |
| 12/05/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $122.89 | General |
| Category: Oncology | ||||||
| 11/15/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $14.99 | General |
| Category: Hematology | ||||||
| 11/01/2023 | Siemens Medical Solutions USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 10/12/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| Category: Oncology | ||||||
| 08/23/2023 | Siemens Medical Solutions USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 527 | 1,039 | $275,920 | $88,879 |
| 2022 | 7 | 446 | 873 | $218,757 | $74,288 |
| 2021 | 10 | 546 | 1,013 | $245,135 | $82,878 |
| 2020 | 9 | 459 | 886 | $198,784 | $58,512 |
Total Patients
1,978
Total Services
3,811
Medicare Billing
$304,556
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 84 | 264 | $76,000 | $26,657 | 35.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 81 | 246 | $69,456 | $21,853 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 117 | 159 | $34,380 | $10,292 | 29.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 53 | 86 | $18,596 | $5,990 | 32.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 50 | $14,500 | $5,194 | 35.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 47 | 50 | $13,876 | $4,244 | 30.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $12,760 | $4,050 | 31.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 57 | $10,963 | $3,364 | 30.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 22 | $11,434 | $2,931 | 25.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $4,923 | $1,664 | 33.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 19 | 46 | $4,998 | $1,620 | 32.4% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 16 | 16 | $4,034 | $1,020 | 25.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 76 | 207 | $57,132 | $21,940 | 38.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 82 | 225 | $59,625 | $17,790 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 109 | 193 | $39,565 | $13,048 | 33.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 17 | 47 | $12,972 | $5,340 | 41.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 31 | 31 | $12,214 | $4,288 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 40 | 58 | $11,890 | $4,257 | 35.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 46 | 49 | $12,936 | $3,971 | 30.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 33 | 51 | $9,435 | $2,729 | 28.9% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 12 | 12 | $2,988 | $926.70 | 31.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 62 | 190 | $52,440 | $20,592 | 39.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 92 | 225 | $59,625 | $17,957 | 30.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 100 | 162 | $33,210 | $11,006 | 33.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 18 | 65 | $17,880 | $7,378 | 41.3% |
About Vikram Gorantla
Vikram Gorantla is a Hematology & Oncology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2008. The National Provider Identifier (NPI) number assigned to this provider is 1528220779.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Vikram Gorantla has received a total of $47,339 in payments from pharmaceutical and medical device companies, with $10,059 received in 2024. These payments were reported across 103 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($31,417).
As a Medicare-enrolled provider, Gorantla has provided services to 1,978 Medicare beneficiaries, totaling 3,811 services with total Medicare billing of $304,556. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Pittsburgh, PA
- Active Since 06/30/2008
- Last Updated 09/23/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1528220779
Products in Payments
- ENHERTU (Biological) $10,649
- Docivyx (Drug) $5,000
- Ogivri (Biological) $4,000
- FERAHEME (Drug) $3,875
- LYNPARZA (Drug) $2,220
- PROVENGE (Drug) $1,635
- Cabozantinib (Drug) $1,523
- Ixempra (Drug) $1,320
- Cabometyx (Drug) $1,320
- Oral Paclitaxel (Drug) $1,250
- KEYTRUDA (Biological) $692.60
- Orserdu (Drug) $423.48
- IBRANCE (Drug) $247.98
- TECENTRIQ (Biological) $119.51
- Trodelvy (Drug) $111.26
- VERZENIO (Drug) $102.52
- Abraxane (Drug) $63.77
- MEKINIST (Drug) $62.21
- Enhertu (Drug) $48.80
- Fulphila (Biological) $43.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Pittsburgh
Salman Fazal, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Cyrus Khan, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Dr. Alexander Barsouk, Md, MD
Hematology & Oncology — Payments: $905,454
Hematology & Oncology $905,454
Taofeek Owonikoko, M.d, M.D
Hematology & Oncology — Payments: $454,396
Hematology & Oncology $454,396
Dr. Hashem Younes, M.d, M.D
Hematology & Oncology — Payments: $451,665
Hematology & Oncology $451,665
Dr. Jason Luke, M.d, M.D
Hematology & Oncology — Payments: $431,360
Hematology & Oncology $431,360